Milestone is a clinical-stage drug development company developing novel small molecule therapeutics based on clinically-validated mechanisms of action for cardiovascular diseases.
At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. These drug hunters proposed small molecule projects based on clinically-proven science that became the foundation of Milestone’s drug development programs.
The Company employs a lean and cost efficient model which has the effect of minimizing overhead and focusing spending on the programs. We have assembled a core seasoned management team with expertise in cardiovascular clinical drug development, regulatory affairs, chemistry and manufacturing, and commercial preparedness which is guided by world-class key opinion leaders (KOLs) and advisors.